Dice Therapeutics to be acquired by Eli Lilly in $2.4 billion deal
David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC Eli Lilly announced on Tuesday that it has entered into a strategic deal valued at $2.4 billion to acquire Dice Therapeutics . This strategic move will strengthen Eli Lilly’s treatment portfolio for immune-related diseases. The deal will involve Eli Lilly acquiring Dice Therapeutics at a price …